Blau syndrome is a dubious disease in the field of autoimmunity and rheumatic immunity, clinical performance is complex and often involves multi-systematic stress. Early identification and standardized clinical care are essential for improving prognosis. The diagnosis of the disease requires a combination of clinical performance, imaging inspection, laboratory testing and pathological activation.
The platform can assist in matching domestic and foreign authoritative experts and teams to provide accurate diagnosis and treatment plans. In recent years, with the development of therapeutic, immune-regulatory therapy and precision medicine, many autoimmune and rheumatic immune diseases that have previously been difficult to treat have been significantly improved. Treatment requires close monitoring of therapeutic efficacy and adverse reactions, adapting to timely schemes according to changes in the condition.
Multidisciplinary collaboration (MDT) is particularly important for the comprehensive management of Blau syndrome. The platform serves the China International Medical Service System, a team of domestically authoritative experts in the field of autoimmune and rheumatic immunity, to provide patients with the following services: Remote pre-diagnosis: Pre-diagnosis by a team of experts reviewing medical records, clear diagnostic directions and medical advice: 1. 2.
Visiting China: arranging face-to-face treatment with authoritative experts, developing individualized treatment programs; 3. Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4. Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of changes in conditions and treatment effects.